8-K: EyePoint Pharmaceuticals Announces Positive Interim Results for DURAVYU in Diabetic Macular Edema Trial

EyePoint Pharmaceuticals reported positive interim data from its Phase 2 VERONA trial, showing significant improvements in vision and retinal thickness for DURAVYU in patients with diabetic macular edema.

Summary

• EyePoint Pharmaceuticals announced positive interim 16-week results from the Phase 2 VERONA clinical trial for DURAVYU in diabetic macular edema (DME).
• The trial evaluated DURAVYU, a sustained-release therapy, against aflibercept, a standard treatment.
• DURAVYU 2.7mg showed an 8.9 letter improvement in best-corrected visual acuity (BCVA) compared to a 3.2 letter improvement with aflibercept.
• Central subfield thickness (CST) improved by 68.1 microns with DURAVYU 2.7mg versus 30.5 microns with aflibercept.
• 82% of patients in the DURAVYU 2.7mg arm were supplement-free at 16 weeks, compared to 50% in the aflibercept arm.
• The company anticipates full topline data from the VERONA trial in the first quarter of 2025.
• EyePoint also has approximately $253.8 million in cash and investments as of September 30, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive interim clinical trial results, a strong cash position, and advancement of multiple clinical programs, indicating a favorable outlook for the company.

Positives

• DURAVYU showed significant improvements in both visual acuity and retinal thickness compared to aflibercept.
• The treatment demonstrated a favorable safety profile with no serious adverse events.
• A higher percentage of patients treated with DURAVYU were supplement-free at 16 weeks compared to the control group.
• The company has a strong cash position with approximately $253.8 million in cash and investments.
• DURAVYU has the potential to reduce the treatment burden for patients with DME and wet AMD.
• The company is advancing multiple clinical trials for DURAVYU in different indications.

Negatives

• The financial results are preliminary and subject to change upon completion of the company's quarterly report.
• The full topline data from the VERONA trial is not expected until Q1 2025.

Risks

• The financial results are preliminary and subject to change.
• Clinical trial results may not be predictive of future outcomes.
• There are uncertainties related to the regulatory approval process for DURAVYU.
• The company's cash and cash equivalents may not be sufficient to support its operating plan.
• There are risks associated with the manufacturing and supply of product candidates.
• The company is subject to a subpoena from the U.S. Attorneys Office and an FDA warning letter.

Future Outlook

EyePoint expects full topline data from the Phase 2 VERONA trial in DME in Q1 2025 and topline data from both Phase 3 pivotal trials in wet AMD in 2026. The company is also advancing other pipeline programs, including EYP-2301.

Management Comments

• Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, stated that they are encouraged and excited by the positive interim results demonstrating clinically meaningful functional and structural improvement with a continued favorable safety profile of DURAVYU.
• Charles Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, noted the significant need for longer-acting treatments for DME and that the interim data suggests promising activity versus aflibercept.
• Adam Gerstenblith, M.D., a principal investigator in the VERONA clinical trial, expressed encouragement by the interim clinical data demonstrating the potential for DURAVYU 2.7mg to extend treatment intervals while improving vision.

Industry Context

The announcement is significant as it addresses the need for more durable treatments for diabetic macular edema, a prevalent disease. The positive results position DURAVYU as a potential competitor to existing anti-VEGF therapies, offering a sustained-release option that could reduce the treatment burden for patients.

Comparison to Industry Standards

• The interim results of DURAVYU in the VERONA trial show a greater improvement in BCVA (+8.9 letters) compared to the aflibercept control (+3.2 letters), suggesting a potential advantage over standard anti-VEGF treatments.
• The reduction in CST with DURAVYU (68.1 microns) is also more significant than with aflibercept (30.5 microns), indicating better anatomical control.
• In the DAVIO 2 trial, DURAVYU demonstrated a substantial reduction in treatment burden, with 82% of patients supplement-free compared to the standard aflibercept treatment, which aligns with the industry's focus on reducing the frequency of injections.
• The results are comparable to other sustained-release therapies in development, but DURAVYU's unique mechanism of action as a pan-VEGF receptor inhibitor could provide a competitive edge.
• The company's focus on a bioerodible insert for drug delivery is consistent with the industry's trend towards more patient-friendly and less invasive treatment options.

Legal Proceedings

• The company is subject to a subpoena from the U.S. Attorneys Office for the District of Massachusetts.
• The company is subject to an FDA warning letter pertaining to its Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising clinical trial results and strong cash position.
• Patients with DME and wet AMD may benefit from a new treatment option with reduced treatment burden.
• Employees may be positively impacted by the company's progress and growth.
• The company's suppliers and partners may benefit from the continued development and potential commercialization of DURAVYU.

Next Steps

• The company will continue the Phase 2 VERONA trial and expects full topline data in Q1 2025.
• The company will continue the Phase 3 LUGANO and LUCIA trials for wet AMD.
• The company will continue development of EYP-2301 and other pipeline programs.

Key Dates

Keywords

DURAVYU, diabetic macular edema, DME, wet AMD, vorolanib, retinal disease, clinical trial, BCVA, CST, aflibercept, sustained release, Durasert E, tyrosine kinase inhibitor